Mayo Clinic Cancer Center | Strategic Alliance Partners

Latest from Mayo Clinic Cancer Center

Personalized Radioembolization Improves OS Vs Standard Dosing in Advanced HCC

March 01, 2021

Yttrium-90 glass microspheres administered in a personalized, dosimetric approach demonstrated a 16-month improvement in overall survival compared with a standard dosimetric approach in patients with unresectable hepatocellular carcinoma.

Targeted Therapies Dominate the Relapsed/Refractory CLL Paradigm

February 27, 2021

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.